News
Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New ...
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
Simultaneously, these higher costs can lead to cuts in business investment and consumer spending, potentially slowing economic growth and leading to layoffs—the very definition of stagflation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results